Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.27) by 29.63 percent. This is a 2.94 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $26.68 million which beat the analyst consensus estimate of $25.53 million by 4.49 percent. This is a 51.05 percent increase over sales of $17.66 million the same period last year.
Galecto’s Myelofibrosis Candidate Reduces Bone Marrow Fibrosis
Galecto Inc (NASDAQ:GLTO) announced results from a planned intermediate assessment of its ongoing MYLOX-1 Phase 2a trial of GB2064 for myelofibrosis.…